NCT07106671 2025-08-06
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Janssen Research & Development, LLC
Centocor, Inc.